Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | DDIT3 | P35638 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631030 | 0.84 | GAA (0.35) | GAAPIK3C3EPHX2SCN9ADDIT3 | |
| SCHEMBL19631000 | 0.81 | PIK3C3 (0.40) | GAAPIK3C3EPHX2SCN9ADDIT3 | |
| SCHEMBL19627365 | 0.81 | CYP2C19 (0.43) | GAACYP2D6CYP2C19 | |
| SCHEMBL19630961 | 0.81 | GAA (0.50) | GAA | |
| SCHEMBL19272299 | 0.79 | GAA (0.53) | GAA | |
| SCHEMBL19630955 | 0.79 | GAA (0.53) | GAA | |
| SCHEMBL19627403 | 0.77 | CYP2D6 (0.36) | GAAPIK3C3EPHX2SCN9ADDIT3 | |
| SCHEMBL1706500 | 0.77 | PIK3C3 (0.33) | PIK3C3 | |
| SCHEMBL3773349 | 0.71 | PIK3C3 (0.32) | PIK3C3 | |
| SCHEMBL7603407 | 0.65 | CYP2D6 (0.47) | CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | SLC10A1, FXR1, SLC10A2 | GAA 892/4885PIK3C3 3585/4885EPHX2 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.